YU49003A - Novi postupak za sintezu fenilamida 5-(4-fluorofenil) -1-(2-((2r,4r)-4-hidroksi-6-okso-tetrahidro-piran-2-il)- etil)-2-izopropil-4-fenil-1h-pirol-3-karboksilne kiseline - Google Patents

Novi postupak za sintezu fenilamida 5-(4-fluorofenil) -1-(2-((2r,4r)-4-hidroksi-6-okso-tetrahidro-piran-2-il)- etil)-2-izopropil-4-fenil-1h-pirol-3-karboksilne kiseline

Info

Publication number
YU49003A
YU49003A YU49003A YUP49003A YU49003A YU 49003 A YU49003 A YU 49003A YU 49003 A YU49003 A YU 49003A YU P49003 A YUP49003 A YU P49003A YU 49003 A YU49003 A YU 49003A
Authority
YU
Yugoslavia
Prior art keywords
pyran
fluorophenyl
pyrrole
tetrahydro
oxo
Prior art date
Application number
YU49003A
Other languages
English (en)
Serbo-Croatian (sh)
Inventor
Ronald Eugene Butler
Randall Lee Dejong
Jade Douglas Nelson
Michael Gerard Pamment
Timothy Lee Stuk
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Publication of YU49003A publication Critical patent/YU49003A/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pyrrole Compounds (AREA)
  • Catalysts (AREA)
YU49003A 2001-01-09 2001-12-27 Novi postupak za sintezu fenilamida 5-(4-fluorofenil) -1-(2-((2r,4r)-4-hidroksi-6-okso-tetrahidro-piran-2-il)- etil)-2-izopropil-4-fenil-1h-pirol-3-karboksilne kiseline YU49003A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26050501P 2001-01-09 2001-01-09

Publications (1)

Publication Number Publication Date
YU49003A true YU49003A (sh) 2006-05-25

Family

ID=22989433

Family Applications (1)

Application Number Title Priority Date Filing Date
YU49003A YU49003A (sh) 2001-01-09 2001-12-27 Novi postupak za sintezu fenilamida 5-(4-fluorofenil) -1-(2-((2r,4r)-4-hidroksi-6-okso-tetrahidro-piran-2-il)- etil)-2-izopropil-4-fenil-1h-pirol-3-karboksilne kiseline

Country Status (25)

Country Link
US (7) US6476235B2 (zh)
EP (1) EP1353917B1 (zh)
JP (2) JP4190285B2 (zh)
KR (3) KR100833911B1 (zh)
CN (4) CN101024626A (zh)
AR (1) AR035680A1 (zh)
AT (1) ATE358126T1 (zh)
BR (1) BR0116739A (zh)
CA (1) CA2432064C (zh)
CY (1) CY1106590T1 (zh)
CZ (1) CZ20031893A3 (zh)
DE (1) DE60127583T2 (zh)
DK (1) DK1353917T3 (zh)
ES (1) ES2282200T3 (zh)
HK (2) HK1060572A1 (zh)
HU (1) HUP0302647A3 (zh)
IL (4) IL156461A0 (zh)
MX (1) MXPA03005284A (zh)
PL (1) PL365283A1 (zh)
PT (1) PT1353917E (zh)
RU (1) RU2244714C1 (zh)
TW (1) TWI293073B (zh)
WO (1) WO2002055519A2 (zh)
YU (1) YU49003A (zh)
ZA (1) ZA200304684B (zh)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7411075B1 (en) 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
US7501450B2 (en) * 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
US6476235B2 (en) * 2001-01-09 2002-11-05 Warner-Lambert Company Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide
US7199261B2 (en) * 2001-07-06 2007-04-03 Teva Pharmaceutical Industries Ltd Process for the preparation of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives via 6-cyano syn 3,5-dihydroxy hexanoic acid derivatives
US20060020137A1 (en) * 2001-11-29 2006-01-26 Limor Tessler Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
PL375415A1 (en) * 2002-08-06 2005-11-28 Warner-Lambert Company Llc Process for preparing 5-(4-fluorophenyl)-1-[2-((2r,4r)-4-hydroxy -6-oxo-tetrahydro-pyran-2-yl)ethyl]-2-isopropyl-4-phenyl-1h-pyrrole-3-carboxylic acid phenylamide
KR100765555B1 (ko) * 2002-08-06 2007-10-09 워너-램버트 캄파니 엘엘씨 5-(4-플루오로페닐)-1-[2-((2ｒ,4ｒ)-4-히드록시-6-옥소-테트라히드로-피란-2-일)에틸]-2-이소프로필-4-페닐-1ｈ-피롤-3-카르복실산 페닐아미드의 제조 방법
EP1480943A2 (en) * 2002-11-15 2004-12-01 Teva Pharmaceutical Industries Limited Synthesis of 3,5-dihydroxy-7-pyrrol-1-yl heptanoic acids
CA2521903A1 (en) 2003-04-14 2004-10-21 Warner-Lambert Company Llc Process for preparing 5-(4-fluorophenyl)-1-[2-((2r,4r)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)ethyl]-2-isopropyl-4-phenyl-1h-pyrrole-3-carboxylic acid phenylamide
US7166638B2 (en) 2003-05-27 2007-01-23 Nicox S.A. Statin derivatives
US7790197B2 (en) * 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US7655692B2 (en) * 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
US20050271717A1 (en) * 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
US20040253305A1 (en) * 2003-06-12 2004-12-16 Luner Paul E. Pharmaceutical compositions of atorvastatin
US7396947B2 (en) * 2003-06-13 2008-07-08 Lanxess Deutschland Gmbh Chiral ligands for application in asymmetric syntheses
AU2004272365A1 (en) * 2003-09-17 2005-03-24 Warner-Lambert Company Llc Crystalline forms of `R-(R*,R*))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-`(phenylamino)carbonyl!-1H-pyrrole-1-heptanoic acid
CN102030645A (zh) 2003-10-24 2011-04-27 隆萨股份公司 6,6,6-三卤-3,5-二氧代己酸酯的制备方法
US20050152323A1 (en) * 2004-01-12 2005-07-14 Vincent Bonnassieux Plug-in Wi-Fi access point device and system
SI21745A (sl) * 2004-04-09 2005-10-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Polimorfi derivata 1-pirol-1-heptanojske kisline, intermediata za pripravo atorvastatina
RU2330840C1 (ru) * 2004-04-16 2008-08-10 Пфайзер Продактс Инк. Способ получения аморфного кальций аторвастатина
ES2739493T3 (es) 2004-05-05 2020-01-31 Pfizer Prod Inc Formas de sal de de atorvastatina con benetamina
CZ299175B6 (cs) * 2004-06-17 2008-05-07 Zentiva, A. S Zpusob stanovení enantiomerní cistoty 2-(4-fluorfenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-fenyl-4[(fenylamino)-karbonyl]-1H-pyrrol-1-heptanové kyseliny a jejích solí
JP5000502B2 (ja) * 2004-07-16 2012-08-15 レツク・フアーマシユーテイカルズ・デー・デー アトルバスタチンカルシウムの酸化分解生成物
CA2672554C (en) 2004-07-20 2012-01-03 Warner-Lambert Company Llc Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl).beta.,.delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1)
PT1773768T (pt) * 2004-07-30 2018-11-30 Exelixis Inc Derivados de pirrol como agentes farmacêuticos
AU2005298383A1 (en) 2004-10-28 2006-05-04 Warner-Lambert Company Llc Process for forming amorphous atorvastatin
CA2589537A1 (en) * 2004-12-02 2006-06-08 Stephen Craig Dyar Pharmaceutical compositions of amorphous atorvastatin and process for preparing same
WO2006067795A2 (en) * 2004-12-23 2006-06-29 Jubilant Organosys Limited Novel polymorphic forms of atorvastatin lactone and process for preparing the same
CA2601111A1 (en) * 2005-03-14 2006-09-21 Pfizer Science And Technology Ireland Limited Preparation of an atorvastatin intermediate using a paal-knorr condensation
EP1705175A1 (en) * 2005-03-24 2006-09-27 ratiopharm GmbH Process for preparing C5 products and their use for Atorvastatin synthesis
CA2547216A1 (en) 2005-09-21 2007-03-21 Renuka D. Reddy Process for annealing amorphous atorvastatin
GB0523637D0 (en) * 2005-11-21 2005-12-28 Avecia Pharmaceuticals Ltd Process and compounds
DE602006014193D1 (de) 2005-11-21 2010-06-17 Warner Lambert Co Neue formen von är-(r*,r*)ü-2-(4-fluorphenyl)-b,d-dihydroxy-5-(1-methylethyl)-3-phenyl-4-ä(phenylamino)carbonylü-1h-pyrrol-1-heptansäure-magnesium
CA2652412A1 (en) * 2006-05-15 2007-11-22 Ratiopharm Gmbh Process for preparing c5 intermediates and their use in the preparation of n-substituted pyrrole derivatives
KR101069698B1 (ko) * 2008-08-28 2011-10-04 한국화학연구원 광학 활성을 갖는 (4ｒ, 6ｒ)-6-(2-아미노에틸)-4-하이드록시-테트라하이드로피란-2-온 유도체의 제조방법
CN101429195B (zh) * 2008-11-03 2010-12-15 华东师范大学 一种高纯度阿托伐他汀重要合成中间体的制备方法
EP2327682A1 (en) 2009-10-29 2011-06-01 KRKA, D.D., Novo Mesto Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
SI2373609T1 (sl) 2008-12-19 2013-12-31 Krka, D.D., Novo Mesto Uporaba amfifilnih spojin za kontrolirano kristalizacijo statinov in intermediatov statinov
EP2473515A4 (en) 2009-09-04 2013-11-27 Univ Toledo METHODS OF MAKING OPTICALLY PURE BETA-LACTONES FROM ALDEHYDES AND COMPOSITIONS OBTAINED THEREFROM
KR100986755B1 (ko) * 2009-12-29 2010-10-08 김우진 노즐 회전장치 및 이를 갖는 분수
CN101892276B (zh) * 2010-06-12 2012-11-21 郝志艳 一种阿托伐他汀钙化合物及其新方法
MX2013002809A (es) 2010-09-16 2013-04-29 Dsm Sinochem Pharm Nl Bv Esteres de acidos hexanoicos.
BRPI1101952B1 (pt) * 2011-04-25 2022-02-01 Universidade Estadual De Campinas - Unicamp Processo de obtenção de atorvastatina cálcica utilizando novos intermediários e atorvastatina assim obtida
US20140335179A1 (en) 2011-07-01 2014-11-13 Dsm Sinochem Pharmaceuticals Netherlands B.V. Micronized crystals of atorvastatin hemicalcium
WO2017137469A1 (en) * 2016-02-11 2017-08-17 Stichting Katholieke Universiteit Novel class of compounds for the treatment of cardiovascular disease
US11513815B1 (en) 2019-05-24 2022-11-29 Hiro Systems Pbc Defining data storage within smart contracts
US10699269B1 (en) * 2019-05-24 2020-06-30 Blockstack Pbc System and method for smart contract publishing
US11657391B1 (en) 2019-05-24 2023-05-23 Hiro Systems Pbc System and method for invoking smart contracts
CN113559318B (zh) * 2021-07-05 2022-09-13 四川大学 一种促神经功能恢复的手性导电修复支架及其制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US5149837A (en) 1988-02-22 1992-09-22 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5097045A (en) 1989-02-01 1992-03-17 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5003080A (en) 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
US5245047A (en) 1988-02-22 1993-09-14 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5124482A (en) 1988-02-22 1992-06-23 Warner-Lambert Company Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis
US5216174A (en) * 1988-02-22 1993-06-01 Warner-Lambert Co. Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5103024A (en) 1990-10-17 1992-04-07 Warner-Lambert Company Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5248793A (en) 1990-10-17 1993-09-28 Warner-Lambert Company Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5155251A (en) 1991-10-11 1992-10-13 Warner-Lambert Company Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate
US5298627A (en) 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
IL128862A (en) 1995-07-17 2007-12-03 Warner Lambert Co [R - (R * R *)] - 2 - (4 - fluorophenyl) - ß, d - dihydroxy - 5 - (1 - methyl - ethyl) 3 - phenyl - 4 - [(phenamino) carbonyl)] - 1H - Pyrol - 1 - Patenoic acid Hydrogen salt Hydrogen crystalline (Atorostatin) Crystalline hydrate
HRP960313B1 (en) 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
WO1997037985A1 (en) * 1996-04-10 1997-10-16 Warner-Lambert Company Nonpeptide endothelin antagonists with increased water solubility
US6087511A (en) 1996-07-16 2000-07-11 Warner-Lambert Company Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
TR199900191T2 (xx) 1996-07-29 1999-04-21 Warner-Lambert Company (S)-3,4-Dihidroksibutirik asitin korumal� esterlerinin sentezi i�in geli�tirilmi� proses.
US6476235B2 (en) * 2001-01-09 2002-11-05 Warner-Lambert Company Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide

Also Published As

Publication number Publication date
HUP0302647A2 (hu) 2003-11-28
EP1353917B1 (en) 2007-03-28
CZ20031893A3 (cs) 2004-03-17
KR100677008B1 (ko) 2007-02-01
US6933393B2 (en) 2005-08-23
CA2432064C (en) 2007-09-11
US20070032663A1 (en) 2007-02-08
PL365283A1 (en) 2004-12-27
JP2004520351A (ja) 2004-07-08
US20030195353A1 (en) 2003-10-16
KR100582326B1 (ko) 2006-05-22
AR035680A1 (es) 2004-06-23
US7399773B2 (en) 2008-07-15
US6545153B1 (en) 2003-04-08
AU2002222430B2 (en) 2007-05-17
CN100351252C (zh) 2007-11-28
KR20060015698A (ko) 2006-02-17
IL189358A0 (en) 2008-06-05
US7183408B2 (en) 2007-02-27
CY1106590T1 (el) 2012-01-25
DE60127583D1 (de) 2007-05-10
HUP0302647A3 (en) 2009-03-30
DE60127583T2 (de) 2007-12-06
US20050239869A1 (en) 2005-10-27
ATE358126T1 (de) 2007-04-15
DK1353917T3 (da) 2007-06-18
PT1353917E (pt) 2007-05-31
JP2008100989A (ja) 2008-05-01
TWI293073B (en) 2008-02-01
MXPA03005284A (es) 2003-09-25
US7371855B2 (en) 2008-05-13
RU2244714C1 (ru) 2005-01-20
EP1353917A2 (en) 2003-10-22
KR20030065594A (ko) 2003-08-06
IL189357A0 (en) 2008-06-05
CN101024626A (zh) 2007-08-29
KR20060114395A (ko) 2006-11-06
CA2432064A1 (en) 2002-07-18
HK1084114A1 (en) 2006-07-21
US6476235B2 (en) 2002-11-05
US20020133026A1 (en) 2002-09-19
CN1696129A (zh) 2005-11-16
WO2002055519A2 (en) 2002-07-18
WO2002055519A3 (en) 2002-09-19
US20070032664A1 (en) 2007-02-08
BR0116739A (pt) 2003-09-30
CN1907984A (zh) 2007-02-07
HK1060572A1 (en) 2004-08-13
ZA200304684B (en) 2004-06-28
IL156461A0 (en) 2004-01-04
IL189359A0 (en) 2008-06-05
US20070032662A1 (en) 2007-02-08
KR100833911B1 (ko) 2008-06-03
US7361771B2 (en) 2008-04-22
JP4190285B2 (ja) 2008-12-03
CN1489587A (zh) 2004-04-14
CN1222521C (zh) 2005-10-12
ES2282200T3 (es) 2007-10-16

Similar Documents

Publication Publication Date Title
YU49003A (sh) Novi postupak za sintezu fenilamida 5-(4-fluorofenil) -1-(2-((2r,4r)-4-hidroksi-6-okso-tetrahidro-piran-2-il)- etil)-2-izopropil-4-fenil-1h-pirol-3-karboksilne kiseline
AU2003202585A1 (en) Disubstituted thiazolyl carboxanilides and their use as microbicides
PL371582A1 (en) Difluoromethyl thiazolyl carboxanilides
MY172828A (en) Process for producing epoxy resins
EA200000358A1 (ru) Способ получения диарилпиридинов, полезных в качестве ингибиторов cox-2
JO2493B1 (en) New phenyl azatidinone with improved physical properties and methods of preparation of drugs containing it and its uses
EA200201264A1 (ru) 5-хлор-3(4-метансульфонилфенил)-6'-метил-[2,3']бипиридинил в чистой кристаллической форме и способ синтеза
DE60123579D1 (de) Synthese von 3,6-dialkyl-5,6-dihydro-4-hydroxy-pyran-2-one
DE60100238D1 (de) Synthese von 3,6-Dialkyl-5,6-Dihydro-4-Hydroxy-2H-Pyran-2-one
RS8604A (en) Process for the production of beraprost and its salts
RS20050105A (en) Process for preparing 5-(4-(54) fluorophenyl)-1-(2-((2r,4r)-4- hydroxy -6-oxo-tetrahydro-pyran-2-yl)ethyl)- 2-isopropyl-4- phenyl-1h-pyrrole-3- carboxylic acid phenylamide
SI1102765T1 (en) PROCESS FOR THE SYNTHESIS OF (1$i(H))-BENZO C)QUINOLIZIN-3-ONES DERIVATIVES
NO994049L (no) Metode for aa fremstille farmasöytiske forbindelser
MY120471A (en) Method for producing enantiomer-free n-methyl-n-[(1s)-1-phenyl-2-((3s)-3-hydroxypyrolidine-1-yl) ethyl]-2, 2-diphenylacetamide.
IL141394A0 (en) Process for the preparation of imidazodiazepine intermediates
MXPA01011104A (es) Procedimiento de sintesis de derivados n-(mercaptoail)-aminoacidos a partir de acidos acrilicos alfa substituidos.
WO2002053537A8 (en) Process for preparing (±) trans-4-p-fluorophenyl-3-hydroxymethyl-1-methylpiperidine
BG104073A (en) Method for preparing alkyloxy furanone derivatives, compounds obtained by said method and use of said compounds
WO2004089894A8 (en) Process for preparing 5-(4-fluorophenyl)-1-[2-((2r,4r)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)ethyl]-2-isopropyl-4-phenyl-1h-pyrrole-3-carboxylic acid phenylamide
GB0015771D0 (en) Cyclic ketones and their use in the synthesis of amino acids
BRPI0514313A (pt) processo para sintetizar um composto, e, composto
JO2498B1 (en) Methods of preparation of derivatives (3-oxy-33,2-2-dihydro-1-isoindol-1-yl)
HRP20020021B1 (en) Method for preparing 2-(2-arylmorpholin-2-yl)ethanol derivatives and intermediates
AU1517601A (en) Method for production of benzofuranone oximes
WO2003080567A3 (en) Intermediates for the synthesis of discodermolide and related analogues and methods for their preparation